Covestor Ltd Sells 278 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Covestor Ltd reduced its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 29.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 670 shares of the company’s stock after selling 278 shares during the period. Covestor Ltd’s holdings in Invesco Biotechnology & Genome ETF were worth $47,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Creative Financial Designs Inc. ADV lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 5.6% in the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after purchasing an additional 299 shares in the last quarter. US Bancorp DE grew its position in shares of Invesco Biotechnology & Genome ETF by 1.8% in the first quarter. US Bancorp DE now owns 16,800 shares of the company’s stock valued at $1,087,000 after purchasing an additional 300 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Invesco Biotechnology & Genome ETF during the second quarter worth approximately $26,000. Investment House LLC grew its position in Invesco Biotechnology & Genome ETF by 6.3% during the second quarter. Investment House LLC now owns 7,635 shares of the company’s stock worth $495,000 after buying an additional 450 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC bought a new stake in Invesco Biotechnology & Genome ETF during the second quarter worth $30,000.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of PBE opened at $66.08 on Friday. The stock has a market capitalization of $266.95 million, a price-to-earnings ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 52 week low of $55.21 and a 52 week high of $72.84. The stock has a fifty day moving average of $69.57 and a 200-day moving average of $67.61.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.